Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Stock Now Rated “Hold” by Wall Street Brokerages

Shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) have been assigned a consensus rating of “Hold” from the five ratings firms that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $38.67.

PHAR has been the subject of several analyst reports. Zacks Research downgraded shares of Pharming Group from a “hold” rating to a “strong sell” rating in a report on Friday, July 31st. Canaccord Genuity Group set a $38.00 price target on shares of Pharming Group in a report on Wednesday, September 23rd. HC Wainwright reiterated a “buy” rating and issued a $37.00 price objective on shares of Pharming Group in a research report on Tuesday, September 22nd. Weiss Ratings reissued a “sell (d)” rating on shares of Pharming Group in a research note on Friday, August 7th. Finally, Oppenheimer restated an “outperform” rating on shares of Pharming Group in a research report on Thursday, July 30th.

Institutional Investors Weigh In On Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. MAC Alpha Capital Management LP bought a new position in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 2,148,144 shares of the company’s stock, valued at approximately $29,838,000. Pharming Group makes up approximately 6.0% of MAC Alpha Capital Management LP’s portfolio, making the stock its 2nd biggest holding. MAC Alpha Capital Management LP owned 3.03% of Pharming Group at the end of the most recent quarter. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Pharming Group Price Performance

Pharming Group stock opened at $9.68 on Friday. The stock has a market capitalization of $685.13 million, a price-to-earnings ratio of 80.67 and a beta of -0.05. Pharming Group has a 52-week low of $9.62 and a 52-week high of $21.34. The stock’s 50 day moving average price is $11.03 and its two-hundred day moving average price is $13.18. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.31 and a current ratio of 3.01.

Pharming Group (NASDAQ:PHAR) last released its earnings results on Thursday, July 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.04). Pharming Group had a net margin of 2.51% and a return on equity of 3.40%. On average, equities analysts predict that Pharming Group will post 0.22 earnings per share for the current year.

Pharming Group Company Profile

Pharming Group N.V. is a global biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and conditions with significant unmet medical needs, using biotechnology and protein-replacement approaches.

Pharming’s commercial products include Ruconest (conestat alfa), a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, and Joenja (leniolisib), an oral therapy for activated phosphoinositide 3-kinase delta syndrome, a rare primary immunodeficiency disorder.